Stoke Therapeutics, Inc. STOK Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32.08M-82.6% | $184.42M-10.3% | $205.63M+2.9% | $199.89M+4.7% | $190.91M+422% | ||
| $144.92M+5.1% | $137.92M+15.3% | $119.65M+14.9% | $104.16M+4.7% | $99.44M+11.6% | ||
| $72.41M+7.9% | $67.09M+14.1% | $58.79M+6.0% | $55.45M— | —— | ||
| $217.33M+6.0% | $205.01M+14.9% | $178.44M+11.8% | $159.61M+4.5% | $152.67M+10.7% | ||
| -$185.25M-800% | -$20.59M-176% | $27.2M-32.5% | $40.28M+5.3% | $38.24M+138% | ||
| -577.5%-566pp | -11.2%-24.4pp | 13.2%-6.9pp | 20.2%+0.1pp | 20%+297pp | ||
| $14.26M+3.7% | $13.76M+4.9% | $13.11M-0.6% | $13.19M+0.7% | $13.1M+3.7% | ||
| $14.2M+3.6% | $13.71M+2.5% | $13.37M-0.8% | $13.48M+1.3% | $13.31M+7.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$169.77M-2,366% | -$6.89M-117% | $40.57M-22.7% | $52.48M+4.4% | $50.27M+156% | ||
| -529.2%-525pp | -3.7%-23.5pp | 19.7%-6.5pp | 26.3%-0.1pp | 26.3%+270pp | ||
| -$2.81-2,242% | -$0.12-118% | $0.68-20.9% | $0.86+7.5% | $0.80+148% | ||
| -$183.52M-875% | -$18.82M-165% | $29.09M-31.2% | $42.27M+4.8% | $40.33M+141% | ||
| -572.1%-562pp | -10.2%-24.4pp | 14.1%-7.0pp | 21.1%0.0pp | 21.1%+292pp | ||
| -$185.25M-800% | -$20.59M-176% | $27.2M-32.5% | $40.28M+5.3% | $38.24M+138% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Stoke Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.